openPR Logo
Press release

Alfa Cytology Unveils In Vitro and In Vivo Models of Cancer for Preclinical Research

08-26-2025 05:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
Alfa Cytology Unveils In Vitro and In Vivo Models of Cancer

Alfa Cytology has unveiled the in vitro and in vivo models of cancer for preclinical research solutions.
New York, USA - August 26, 2025 - Alfa Cytology, a cancer therapeutic development and preclinical research solution provider, announced a full-service approach to cancer research with the addition of in vitro and in vivo models of cancer [https://www.alfacytology.com/cancer-modeling-services.html]. The company's objective is to revolutionize the preclinical stage of drug development with high-quality and reproducible models, offering cancer researchers a deeper understanding of cancer mechanisms and the opportunity to screen the effectiveness of potential therapeutics.

Image: https://www.globalnewslines.com/uploads/2025/08/a17b7ed1da71cb24749496712dec493d.jpg

In recent years, cancer research has evolved to demand more precise and predictive models, as limitations with traditional in vitro cell cultures and animal models have been identified, specifically when these methods are unable to accurately represent the complex biology of human cancers. Alfa Cytology has developed an extensive line of in vitro and in vivo models of cancer to provide an integrated approach to cancer research that can be customized to meet the needs of researchers.

Alfa Cytology's in vitro models of cancer provide researchers with human-derived cell lines, organoids, and 3D culture systems that can more accurately represent the tumor microenvironment and offer a viable platform for the screening of therapeutic compounds. These in vitro systems can help to identify and optimize drug candidates early in the discovery process by testing for cytotoxicity, efficacy, and mechanism of action. Furthermore, the ability to replicate tumor growth and response to therapy in vitro can help to create a foundation for in vivo validation and decrease the time and resources wasted on non-viable drug candidates.

In vivo models of cancer offered by Alfa Cytology are also a crucial part of the preclinical research process, providing researchers with a more clinically relevant setting for studying the pharmacokinetics, pharmacodynamics, and safety profiles of cancer therapeutics. Alfa Cytology offers humanized animal models, patient-derived xenograft (PDX), and syngeneic mouse models that can provide more reliable and reproducible results for tumor response to new compounds. These animal models can also be used to study tumor progression, metastasis, and drug resistance, providing researchers with valuable insights into the therapeutic potential of drug candidates before the clinical trial phase.

Alfa Cytology's in vitro and in vivo models of cancer are essential for streamlining the drug discovery and development process, from the identification of lead compounds to the optimization of drug candidates and the determination of the most effective dosing regimens. By providing a more complete picture of drug efficacy and safety, Alfa Cytology's models can help researchers make better-informed decisions at every stage of therapeutic development and reduce the risk of late-stage failures that can be extremely costly.

The models provided by Alfa Cytology also offer critical insights into the molecular and cellular mechanisms driving cancer biology, allowing researchers to study gene expression, protein biomarkers, and cellular interactions within the tumor microenvironment. By better understanding the underpinnings of cancer, new therapeutic targets and treatment strategies can be identified and optimized. Alfa Cytology also provides services beyond model development, including pharmacological analysis, biomarker identification, and biomolecular assays to ensure that each research project is specifically tailored to meet the needs of the research objectives.

About Alfa Cytology

Headquartered in New York, Alfa Cytology is a cancer therapeutic development and preclinical research solution provider [https://www.alfacytology.com/]. Specializing in advanced in vitro and in vivo models of cancer, Alfa Cytology offers a range of services to support the oncology research community, from model development and validation to pharmacological analysis and biomolecular assays. With a team of experts in molecular biology, oncology, and pharmacology, Alfa Cytology has the experience and expertise to provide tailored research solutions to meet the unique challenges of cancer drug development.
Media Contact
Company Name: Alfa Cytology
Contact Person: David Thomas
Email: Send Email [http://www.universalpressrelease.com/?pr=alfa-cytology-unveils-in-vitro-and-in-vivo-models-of-cancer-for-preclinical-research]
Country: United States
Website: https://www.alfacytology.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alfa Cytology Unveils In Vitro and In Vivo Models of Cancer for Preclinical Research here

News-ID: 4160400 • Views:

More Releases from Getnews

INVIROX Reveals: This Is How Dog Owners Kill Dog Training Sessions
INVIROX Reveals: This Is How Dog Owners Kill Dog Training Sessions
Uncovering the Hidden Habits Sabotaging Dog Training Success and How Calm Tools Can Transform Every Session. Image: https://www.globalnewslines.com/uploads/2025/10/f070e9fcd4110d5250be0576b818caa1.jpg Dog owners across the country often begin training sessions with enthusiasm and end in frustration. The dog's tail wags, excitement builds, and within minutes, the session unravels into a frenzy of barking, jumping, and chaos. Most training failures occur before real learning begins, and the problem often lies not with the dog but with
EasyHired.com Launches AI Platform That Automatically Applies to Jobs for Busy Professionals
EasyHired.com Launches AI Platform That Automatically Applies to Jobs for Busy P …
EasyHired.com has launched an AI-driven automation platform that applies to jobs on behalf of professionals, aiming to remove the repetitive friction of online applications while improving interview throughput. The company says the system searches, matches, and submits tailored applications across global job boards and employer sites, freeing candidates to focus on interview preparation rather than form-filling. Image: https://www.globalnewslines.com/uploads/2025/10/0bba76e7413063bba8ca8fe879d3fcfc.jpg According to EasyHired [https://easyhired.com/], the platform analyzes resume keywords, job descriptions, and employer requirements,
Cart Capital Grants Select Partners Access to Its Exclusive eCommerce Growth Infrastructure
Cart Capital Grants Select Partners Access to Its Exclusive eCommerce Growth Inf …
Cart Capital, a Miami-based eCommerce company, is redefining the standard for online business ownership through its private, performance-based partnership model. Designed for individuals seeking structured, scalable, and fully managed eCommerce growth, Cart Capital provides exclusive access to one of the most comprehensive infrastructures in the digital commerce space today. Image: https://www.globalnewslines.com/uploads/2025/10/43bf8a01bc29227830611e88c4d73bb6.jpg Unlike traditional agencies or service providers, Cart Capital does not operate on a public, open-enrollment model. Instead, the company selectively partners
HOSA Partners with International Medical Aid to Offer Exclusive Clinical Internships for High School Students
HOSA Partners with International Medical Aid to Offer Exclusive Clinical Interns …
HOSA-Future Health Professionals announced an official partnership with International Medical Aid (IMA), naming IMA as its premier provider of clinical opportunities for high school students. Through this collaboration, HOSA members across the United States and globally will gain priority access to IMA's clinically intensive, patient-facing programs designed specifically for high school students seeking meaningful, ethical exposure to healthcare. Image: https://www.globalnewslines.com/uploads/2025/10/269f5d3f1ee3d3bc9659584ff528630a.jpg International Medical Aid [https://medicalaid.org/], a leading global provider of healthcare internships and

All 5 Releases


More Releases for Alfa

Biological Treatment Technologies Market May Set Epic Growth Story | Alfa-Therm, …
Pro Market Reports published a new research publication on "Biological Treatment Technologies Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Biological Treatment Technologies market was mainly driven by the increasing R&D spending across the world. Some of the key players
New Pump Handbook from Alfa Laval
Alfa Laval just published a brand new edition of the company's renowned Pump Handbook. The 375-page handbook is free and contains scholarly information on basic pump functionality and in-depth guidelines for sizing and selecting the right pump type for optimum efficiency. The handbook is packed with real-life examples to increase its user-friendliness. The first edition of the Alfa Laval Pump Handbook was published 25 years ago and soon became part of
Salicylic Acid Market Growth Potential is Booming Now: Alfa Chemistry, Novacap G …
HTF Market Intelligence recently released a survey document on the Salicylic Acid market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision-makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, and emerging trends along with essential drivers, challenges, opportunities, and restraints in
Hybrid Heat Exchanger Market 2020 Strategic Assessment - Alfa Laval AB(STO: ALFA …
"Global Hybrid Heat Exchanger Market Report 2020-2026" helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market - driven results deriving feasibility studies for client needs. Marketinsightsreports ensures qualified and verifiable aspects of market data operating in the real- time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in
Alfa Chemistry Launched Microalgae Powder Services
On October 24, 2019, Alfa Chemistry announced that it has launched microalgae powder production services. Alfa Chemistry is a high-tech company specializing in the cultivation of microalgae powder and the production of related natural extracts. It has obtained more than 75 patents in the breeding, cultivation, processing and extraction of microalgae, serving customers in the feed, food, nutraceutical and pharmaceutical sectors. At present, the annual production capacity of Alfa Chemistry's microalgae
Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80% of Global Erythropoie …
Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). This erythropoietin (EPO) drugs are used for the treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to the development of synthetic forms of erythropoietin such as epoetin